StockData

Gilead Sciences vs Viatris

GILD and VTRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GILD and VTRS compare

Gilead Sciences is the larger company, worth 8.7 times as much as Viatris ($208B against $23.8B).

Gilead Sciences grew revenue faster over the last twelve months (6.5% versus 4.4% for Viatris).

Both pay dividends: Gilead Sciences yields 1.9% and Viatris 2.3%.

Gilead Sciences scores higher on the StockData Score (12 against 6 for Viatris), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGILDVTRS
Size and price
Market cap$208B$23.8B
Share price$167.58$20.74
Change, 1 year33.8%90.1%
Change, 5 years138%62.7%
Beta (5Y)0.150.32
Employees17K30K
StockData Score
Total score12 (better)6
Valuation score02 (better)
Growth score3 (better)1
Performance score3 (better)0
Health score3 (better)1
Dividend score3 (better)2
Valuation
P/S6.7×1.6× (better)
P/B15.9×–
EV/EBITDA–13.4×
P/FCF15.1×12.2× (better)
FCF yield6.6%8.2% (better)
Fair value$84.23$22.57
Margin of safety−98.9%8.1% (better)
Growth
Revenue growth (TTM)6.5% (better)4.4%
Revenue growth, 5Y average3.6%3.7% (better)
Net income growth (TTM)−148%–
EPS growth (TTM)−149%–
EPS growth, 5Y average132%–
Profitability
Gross margin79.9% (better)34.8%
Operating margin−7.6%−0.59% (better)
Net margin−12.5%–
FCF margin44.5% (better)13.3%
Return on equity−22.3%–
Return on invested capital−5.2%–
Financial health
Debt / equity2.01–
Net debt / EBITDA–4.59
Interest coverage−2.3×−0.2× (better)
Current ratio1.381.58 (better)
Altman Z-score3.89 (better)1.21
Piotroski F-score8–
Dividends and buybacks
Dividend yield1.9%2.3% (better)
Years of dividend growth11 (better)0
Dividend growth, 5Y average3.0%–
Buyback yield0.52%1.3% (better)
Shareholder yield2.5%3.6% (better)
Ownership
Held by institutions89.8%91.5%
Held by insiders0.10%0.36%
Insider net buying, 12 months−$99.2M−$1.1M (better)
Superinvestors holding–3
Short interest, % of float1.7%3.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.